Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma

Marije B Overdijk1, Sandra Verploegen1, Marijn Böngels2,3, Marjolein van Egmond2,3, Jeroen J Lammerts van Bueren1, Tuna Mutis4, Richard WJ Groen5, Esther Breij1, Anton CM Martens5,6, Wim K Bleeker1, and Paul WHI Parren1,7,8,*

1Genmab; Utrecht, The Netherlands; 2Department of Molecular Cell Biology and Immunology; VU University Medical Center; Amsterdam, The Netherlands; 3Department of Surgery; VU University Medical Center; Amsterdam, The Netherlands; 4Department of Clinical Chemistry and Hematology; University Medical Center; Utrecht, The Netherlands; 5Department of Cell Biology; VU University Medical Center; Utrecht, The Netherlands; 6Department of Immunology; University Medical Center; Utrecht, The Netherlands; 7Department of Cancer and Inflammation Research; Institute of Molecular Medicine; University of Southern Denmark; Odense, Denmark; 8Department of Immunohematology and Blood Transfusion; Leiden University Medical Center; Leiden, The Netherlands

Keywords: macrophage, phagocytosis, therapeutic antibody, CD38, daratumumab, multiple myeloma, Burkitt’s lymphoma

Abbreviations: ADCC, antibody-dependent cellular cytotoxicity; BM, bone marrow; BL, Burkitt’s lymphoma; CDC, complement-dependent cytotoxicity; CCS, cosmic calf serum; DARA, daratumumab; DP, double positive; E:T, effector to target ratio; FcγR, Fc-gamma receptor; IMiD, immunomodulatory drug; Mφ, macrophage; mAb, monoclonal antibody; MNC, mononuclear cells; MM, multiple myeloma; PBMC, peripheral blood mononuclear cells

Daratumumab (DARA) is a human CD38-specific IgG1 antibody that is in clinical development for the treatment of multiple myeloma (MM). The potential for IgG1 antibodies to induce macrophage-mediated phagocytosis, in combination with the known presence of macrophages in the tumor microenvironment in MM and other hematological tumors, led us to investigate the contribution of antibody-dependent, macrophage-mediated phagocytosis to DARA’s mechanism of action. Live cell imaging revealed that DARA efficiently induced macrophage-mediated phagocytosis, in which individual macrophages rapidly and sequentially engulfed multiple tumor cells. DARA-dependent phagocytosis by mouse and human macrophages was also observed in an in vitro flow cytometry assay, using a range of MM and Burkitt’s lymphoma cell lines. Phagocytosis contributed to DARA’s anti-tumor activity in vivo, in both a subcutaneous and an intravenous leukemic xenograft mouse model. Finally, DARA was shown to induce macrophage-mediated phagocytosis of MM cells isolated from 11 of 12 MM patients that showed variable levels of CD38 expression. In summary, we demonstrate that phagocytosis is a fast, potent and clinically relevant mechanism of action that may contribute to the therapeutic activity of DARA in multiple myeloma and potentially other hematological tumors.

Introduction

Phagocytosis is an efficient and fast mechanism for the elimination of pathogens and apoptotic cells. Phagocytosis can be induced through several pathways, including recognition of surface-bound antibodies (Ab), complement factors or pathogen-associated molecular patterns. Antibody-dependent phagocytosis of IgG1-opsonized pathogens as well as cancer cells occurs via binding to Fcγ-receptors (FcγRs), specifically via the low-affinity receptors FcγRIIa and FcγRIIIa.1,2

Macrophages (Mφ), representing professional phagocytes, are abundant in tumor stroma3,5 and phagocytosis by Mφ might therefore be a very potent mechanism of action of therapeutic Ab in cancer treatment.

By using mouse strains deficient in specific leukocyte subpopulations or by depleting specific effector cell subsets, Mφ were shown to represent the main effector cells in the anti-tumor activity of CD20-targeting monoclonal Ab (mAb) in vivo.6,7 Furthermore, for SGN-30 (chimeric IgG1 CD30 mAb), SGN-40 (humanized IgG1 CD40 mAb) and a humanized CD70 mAb,
all of which were shown to mediate phagocytosis in vitro, mAb were shown to be the major effector cells in vivo.\(^8\),\(^9\)\(^,\)\(^10\)

Daratumumab (DARA) is a human IgG1 mAb targeting CD38, a 46-kDa type II transmembrane glycoprotein that is expressed at high levels on malignant cells in multiple myeloma (MM).\(^1\)\(^1\)\(^1\) DARA was granted Breakthrough Therapy Designation by the Food and Drug Administration for MM patients who have received at least 3 prior lines of therapy including a proteasome inhibitor and an immunomodulatory agent, or patients double refractory to these agents, in 2013, and it is currently in multiple Phase 3 clinical trials for the treatment of MM. DARA can induce tumor cell killing through a number of effector mechanisms, including the Fc-dependent effector mechanisms complement-dependent cytotoxicity (CDC) and natural killer (NK)-cell mediated antibody-dependent cellular cytotoxicity (ADCC).\(^1\)\(^2\) Macrophages are known to be abundantly present in the bone marrow of MM patients,\(^4\),\(^5\) and macrophage-mediated phagocytosis has been demonstrated to be induced by several mAbs targeting MM cells.\(^1\)\(^3\),\(^1\)\(^4\) The capacity of DARA to induce macrophage-mediated phagocytosis has not been studied thus far.

Here, we explored the capacity of DARA to kill tumor cells through antibody-dependent phagocytosis. DARA-dependent phagocytosis of Burkitt’s lymphoma (BL) and MM cell lines in vitro was explored using live cell imaging and flow cytometry. Furthermore, DARA-dependent phagocytosis of patient-derived MM cells was studied ex vivo. Finally, the contribution of phagocytosis to the anti-tumor activity of DARA in vivo was studied using an isotype variant of DARA that does not induce phagocytosis in the presence of mouse macrophages. Our results showed that phagocytosis contributes to the anti-tumor activity of DARA in vitro and in vivo.

**Results**

**DARA induces phagocytosis of CD38-positive tumor cells**

To explore the induction of phagocytosis by DARA, we set up a flow cytometric phagocytosis assay using mouse mAb as effector cells and Burkitt’s lymphoma (BL) Daudi cells as target cells. Phagocytosis was assessed in 2 ways: 1) by determining the percentage of double positive (DP) mAb (representative flow cytometry plots shown in Fig. S1) and 2) by determining the percentage of eliminated target cells (calculated as described in Materials & Methods). DARA induced macrophage-mediated phagocytosis, as shown by an increase in the number of DP mAb (Fig. 1A) and elimination of a substantial proportion of target cells (Fig. 1B). Live cell imaging confirmed that this increase in DP mAb and eliminated target cells was indeed due to DARA-dependent phagocytosis. Supplemental movie 1 shows time-lapse imaging microscopy of co-cultures of DiO (green) labeled mouse mAb and DiB (blue) labeled Daudi cells in the presence of DARA. All target cells visible in the field of observation had been phagocytosed at the end of the experiment. Interestingly, using time-lapse imaging microscopy, we frequently observed mAb to engulf multiple DARA-opsonized target cells in a relatively short time span. Fig. 1C and Supplemental movie 2 show an individual mouse mAb (designated with an arrow) that sequentially engulfed 5 individual Daudi cells (numbers) over a period of 800 s. The images are representative for observations in multiple independent phagocytosis experiments (n = 3) (**p < 0.0001 Bonferroni’s multiple comparison test).

**Threshold CD38 expression level for phagocytosis induction**

To explore the effect of CD38 expression levels on phagocytosis induction by DARA, we set up a flow cytometric assay with mouse mAb and leukemic target cells with variable levels of CD38.
Ranges based on at least 3 independent experiments.

| Cell Line | CD38 range (molecules/cell) | DP mφ range(%) | Elimination range(%) |
|-----------|-----------------------------|----------------|---------------------|
| Wien-133  | 100,000~150,000             | 5–20           | 0–40                |
| Raji      | 150,000~350,000             | 7–15           | 0–10                |
| Ramos     | 200,000~300,000             | 12–25          | 0–20                |
| Daudi     | 200,000~400,000             | 12–40          | 29–79               |
| UM9-CD38  | 350,000~600,000             | 5–8            | 2–50                |
| L363-CD38 | 450,000~800,000             | 9–10           | 4–70                |

Phagocytosis contributes to the anti-tumor activity of DARA in vivo

We previously demonstrated that, in contrast to human IgG1, the human IgG2 isotype shows weak to no phagocytosis activity with mouse mφ. Therefore, we compared DARA to a DARA-IgG2 isotype variant to study the contribution of phagocytosis to the in vivo efficacy of DARA in mouse xenograft tumor models. To restrict in vivo effector cell activity to mouse mφ, we made use of immune-deficient SCID-BEIGE mice, which lack B, T and NK cells. ADCDC mediated by mφ is not expected to contribute in vivo, as we did not observe extracellular lysis after 24 h incubation of Daudi cells with mφ in the presence of DARA (Fig. S3). To exclude CDC, a known effector mechanism of DARA, Fc mutants were generated in which the lysine residue at position 322 was mutated to alanine (referred to as DARA-K322A and DARA-IgG2-K322A). Duncan et al. and Idusogie et al. showed K322 to be a critical residue for human C1q binding and complement activation, and we recently confirmed that the K322A mutation also leads to strongly reduced binding of mouse C1q. The K322A mutation itself did not affect the capacity of DARA to induce macrophage-mediated phagocytosis in vitro, as shown by similar percentages of both DP mφ and eliminated target cells induced by DARA and DARA-K322A (Fig. 2A and B). The percentage of DP mφ was strongly reduced when the DARA-IgG2-K322A variant was used instead of DARA or DARA-K322A. In addition, the percentage of eliminated target cells was significantly lower with the DARA-IgG2-K322A variant. This confirms that phagocytic capacity was preserved in DARA-K322A, whereas DARA-IgG2-K322A showed strongly impaired phagocytic capacity.

In a subcutaneous Daudi-luc tumor xenograft model, DARA-K322A provided significantly stronger inhibition of tumor growth than DARA-IgG2-K322A (Fig. 3A), indicating an important contribution of phagocytosis to the in vivo efficacy of DARA. Furthermore, in the intravenous leukemic Daudi-luc xenograft model, in which mice were treated at the time of tumor challenge, DARA-K322A also demonstrated a significantly stronger tumor growth inhibition compared to DARA-IgG2-K322A (Fig. 3B). Upon therapeutic treatment in this leukemic Daudi-luc xenograft model, DARA-K322A also showed better potency than DARA-IgG2-K322A (treatment with 0.5 mg/kg at day 14), as shown in Fig. S2. These data demonstrate that phagocytosis contributes to the in vivo mechanism of action of DARA.

![Figure 2](image-url)
**Discussion**

In this study we investigated the capacity of DARA to induce macrophage-mediated phagocytosis and we observed that mouse and human mAb-phagocytosed several CD38-positive BL and MM cell lines in the presence of DARA. Importantly, DARA was able to induce human macrophage-mediated phagocytosis of MM cells from 11 of 12 MM patients. Phagocytosis of patient MM cells by human mAb appeared to be more efficient than for the MM cell lines. Finally, phagocytosis was shown to contribute to the anti-tumor activity of DARA in vivo, in 2 different xenograft models.

Time-lapse imaging microscopy studies demonstrated that some macrophages engulfed multiple DARA-opsonized target cells, whereas other macrophages did not show phagocytic capacity. Comparison of different effector-to-target ratios revealed that, in all cases, only a maximum of ~40% of mouse mAb actively engulfed one or multiple target cells (data not shown). Examining different target cell lines, we observed that the percentage of DP mAb was more or less comparable for all cell lines, whereas there was a striking difference in the percentage of eliminated target cells. This difference might be due to the number of target cells engulfed per mAb or it might be due to a difference in rate of phagocytosis between cell lines. Overall, the combination of the percentage of DP macrophages and the percentage of eliminated target cells provided an adequate representation of phagocytic capacity.

Although the capacity of DARA to induce phagocytosis was to some extent related to CD38 expression levels on target cells, differences in phagocytosis-mediated elimination of different target cell lines could not solely be explained by the differences in CD38 expression level, which confirms previous findings of Leidi et al. They compared phagocytosis of rituximab (chimeric IgG1 CD20 mAb) opsonized B-chronic lymphocytic leukemia and mantle cell lymphoma cells by human mAb and found that, although CD20 expression was required for rituximab-dependent phagocytosis, CD20 expression levels did not correlate with phagocytosis activity, as was also observed for ADCC. In contrast, target expression was previously shown to significantly affect CDC. Target cell size and shape have been suggested to influence phagocytosis efficacy and a model was proposed for size-dependent transitions that may determine whether a target cell will be phagocytosed or not. Cell size of the different BL and MM cells used in our study appeared to be comparable; very low levels of CD38 (~10,000 molecules/cell) that were found insensitive to DARA-dependent phagocytosis. Based on these observations we conclude that phagocytosis is a relevant and powerful effector mechanism of DARA, and for patient-derived MM cells.

---

**Figure 3. Phagocytosis contributes to the in vivo anti-tumor effect of DARA.** (A) Kaplan-Meier plot showing time to tumor progression (cutoff set at a tumor volume > 800 mm³) for mice that had been inoculated s.c. with 20 × 10⁶ Daudi-luc cells (8 mice per group). Subsequently, mice were treated i.p. with 250 µg mAb per mouse (~1.25 mg/kg) at day 0. Tumor progression was significantly reduced in DARA-K322A-treated mice compared to DARA-lgG2-K322A treatment (p < 0.004 Mantle-Cox log-rank test at time to progression). (B) Kaplan-Meier plot showing time to tumor progression (cutoff set at bioluminescence > 50 000 cpm) for mice that had been inoculated i.v. with 2.5 × 10⁶ Daudi-luc cells (10 mice per group). Subsequently, mice were treated i.p. with 10 µg mAb per mouse (~0.5 mg/kg) at day 0. Tumor progression was significantly reduced in DARA-K322A-treated vs. DARA-lgG2-K322A-treated mice (p < 0.001 Mantle-Cox log-rank test at time to progression).

---

**Patient MM tumor cells are efficiently phagocytosed by human macrophages in presence of DARA**

To translate our observations from xenograft tumor models to patients, we explored DARA-dependent phagocytosis of patient MM cells with human mAb. Monocytes isolated from healthy donors were cultured in the presence of granulocyte-macrophage colony-stimulating factor (GM-CSF) and characterized as CD11b⁺CD64⁺CD32⁺CD16₁⁻₁⁻ mAb (data not shown). First, we explored the efficacy of phagocytosis by human mAb in presence of DARA using BL cell lines Daudi and Ramos, or MM cell lines UM9-CD38 and L363-CD38. Again, phagocytosis was assessed by determining the percentage DP mAb and percentage eliminated target cells. Fig. 4A and B show the percentage DP mAb and eliminated target cells, respectively, using BL and MM cell lines. Human mAb enhanced phagocytosis of DARA-opsonized tumor cells relative to background levels in the presence of DARA F(ab')₂ fragments or irrelevant mAb control. Second, we explored DARA-dependent phagocytosis of patient MM cells obtained from either bone marrow (BM), pleural fluid or blood. The MM patient samples contained more than 60% plasma cells, characterized as CD138⁺ cells. CD38 expression ranged from 10,000 to 550,000 molecules/cell (Table 2). Peripheral blood, from 7 different healthy donors for which the FcγRIIa and IIIa-polymorphism were determined (Table 2), was used as a source of human mAb. As the potency of the human mAb differed between experiments, most likely due to differences in macrophage batches obtained from different donors, Daudi cells were included in each experiment as an internal control (see Materials & Methods). Fig. 5A and B show normalized percentages of DP mAb and eliminated target cells, respectively, calculated from the ratio of patient MM cells and the internal Daudi cell standard. For 11 of 12 patients, efficient DARA-dependent phagocytosis was observed, except for patient 6, for which MM cells expressed
however, difference in shape might account for the difference in phagocytosis efficiency. In addition to target expression levels, target cell size and shape, so-called ‘don’t eat me’ signals on target cells play an important role in regulating phagocytosis. A prominent example is CD47, which inhibits phagocytosis via ligation to its receptor SIRPα on the phagocytic cell.25 CD47 is described to be upregulated on leukemic cells to avoid phagocytosis,26 which can be counterbalanced by the expression of calreticulin that gives a pro-phagocytic signal upon receptor binding.27,28 Human CD47 is not able to bind to mouse SIRPα,29,30 and therefore CD47 cannot account for the difference in phagocytosis efficiency with mouse mφ. Overall, there might be other, yet undefined, regulators of phagocytosis and this possibility needs further investigation.

In vivo studies that address the role of mφ contributing to the mechanism of action of mAbs via mφ depletion, cannot discriminate between macrophage-mediated phagocytosis and macrophage-mediated ADCC. Therefore, we compared the efficacy of DARA with a matched IgG2 isotype variant that did not induce phagocytosis by mouse mφ. DARA induced significantly stronger tumor growth inhibition compared to the IgG2 variant in both a subcutaneous as well as a leukemic intravenous Daudi-luc xenograft model. Upon therapeutic treatment in the leukemic Daudi-luc xenograft model, DARA was also more potent compared to the IgG2 variant. Because macrophage-mediated ADCC is not expected to contribute to the anti-tumor effect of DARA and DARA-IgG2 (Fig. S3 and Reference 16), these experiments confirm a significant role for macrophage-mediated phagocytosis in vivo. It is noted that DARA-IgG2 still induced significantly stronger tumor growth inhibition compared to the control in both models. As (1) a contribution of CDC was excluded in our experiments by using complement activation-deficient K322A mutant, and (2) a contribution of ADCC mediated by NK cells was excluded by selecting SCID-BEIGE lacking B, T and NK cells, potential other anti-tumor effects of DARA and DARA-IgG2 require further study. Such mechanisms could include the modulation of CD38 ectoenzyme function31 by DARA or the induction of polymorphonuclear neutrophil-mediated ADCC, which was shown to be similar for IgG1 and IgG2 antibodies targeting epidermal growth factor receptor.16,32

Overall, our results demonstrated a role for mφ-mediated phagocytosis in the in vivo mechanism of action of DARA in preclinical models. The contribution of phagocytosis to the in vivo efficacy for CD20-targeting mAb was recently shown. CD20 mAb treatment resulted in depletion of B cells in blood and liver within 2 hours.33 After partial hepatectomy, the efficiency of B-cell depletion in the blood was reduced, indicating that the liver contributes to the B-cell depletion in blood. Intravital imaging demonstrated depletion of B cells in the liver via phagocytosis by resident liver mφ (Kupffer cells). With live cell imaging in vitro, we also observed that DARA-dependent phagocytosis is a very

Figure 4. Human macrophages induce DARA-dependent phagocytosis of BL and MM cell lines. Phagocytosis of BL cells (left panel) or MM cells (right panel) by human mφ in the presence of 6.7 nM mAb, E:T ratio of 2:1. (A) Percentage of double positive (DP) mφ characterized as CD11b^ + calcein^-target Ag^- . (B) Percentage of eliminated target cells calculated from the number of remaining CD11b^- cells as described in Materials & Methods. Each bar shows mean ± SEM, results from a representative experiment (n = 3) (**p < 0.01, ***p < 0.001, ****p < 0.0001 Bonferroni’s multiple comparison test).
fast mechanism. Delineation of the site of DARA-mediated phagocytosis in vivo, either in situ by tumor macrophages or via the reticuloendothelial system, requires further investigation.

In view of the high potential of DARA in MM, we explored the efficacy of DARA-dependent macrophage-mediated phagocytosis on patient MM cells. Potent DARA-dependent phagocytosis of MM cells was observed in 11 of 12 patient samples ex vivo, indicating that phagocytosis is a potential mechanism of action for DARA. The normalized results for DP mϕ were lower than 100 percent for most of these MM patients, indicating that the percentage of macrophages that showed phagocytic activity was lower with MM patient cells than with Daudi cells. In contrast, the normalized percentage of eliminated target cells was 100 percent for most of these MM patients, indicating that the efficacy of DARA-induced phagocytosis in the BM. Another approach is the combination with drugs regulating anti-phagocytic signals. Anti-CD47 mAb has been shown to synergize with rituximab in the treatment of non-Hodgkin lymphoma. Moreover, targeting the CD47-SIRP α axis has now been shown to increase efficacy of several therapeutic antibodies. CD47 is described to be highly expressed on MM cells, suggesting that inhibition of the CD47-SIRP α axis might be an interesting therapeutic approach in combination with DARA.

Overall, we have shown that DARA induces macrophage-mediated phagocytosis of BL and MM cancer cell lines and MM patient cells. The enhanced efficacy of DARA-K322A versus DARA-IgG2-K322A in a subcutaneous and a leukemic intravenous xenograft tumor model suggests that phagocytosis also contributes to the efficacy of DARA in vivo. We conclude that phagocytosis is a rapid and potent mechanism of action that may contribute to the therapeutic activity of DARA in MM patients.

### Materials and Methods

#### Cell lines
Raji, Ramos and Daudi-cells (human BL) were obtained from the ATCC (CCL-86, CRL-1596 and CCL-213, respectively). Wien-133 cells were kindly provided by Dr. Geoff Hale (BioAnaLab Limited, Oxford, UK). Daudi cells were transfected with gWIZ luciferase as previously described (Daudi-luc). The MM cell lines UM-9, generated at the University Medical Center (Utrecht, the Netherlands), and L363, obtained from the ATCC and gene-marked with GFP and luciferase marker genes, were transduced with human CD38 gene to obtain CD38 expression levels comparable to primary myeloma cells. For this, the amphotropic Phoenix packaging cell line (Phoenix Amphi) was transduced, using calcium phosphate precipitation, with the pQCXIN vector in which the gene encoding human CD38 was inserted. These cell lines are referred to as UM9-CD38 and L363-CD38. Cells were cultured in IMDM medium.
Mononuclear cells (MNC) from MM patients, isolated from the bone marrow, pleural fluid or blood, were obtained after informed consent and approval by the Medical Ethical Committee (University Medical Center, Utrecht, The Netherlands).

**Antibodies**

Human IgG1 CD38 mAb DARA was generated by immunization in a HuMAb mouse and produced as recombinant protein as described previously.\(^\text{12}\) DARA F(ab’\(^2\)) fragments were prepared via pepsin digestion (Sigma-Aldrich, P7012). An IgG2 variant of DARA (DARA-IgG2) was constructed by cloning the variable region of the immunoglobulin heavy chain (\(V_\text{H}\)) of DARA into a human IgG2 backbone. The human heavy chain construct was co-expressed with the appropriate original human kappa light chain. Fc mutants were generated by mutating the lysine residue at position 322 to alanine; these mutants are referred to as DARA-K322A and DARA-IgG2-K322A. The mutations were introduced as described previously.\(^\text{16,19}\) The human mAb IgG1 b12, specific for the HIV-1 gp120 envelope glycoprotein,\(^\text{47}\) was included in all experiments as an irrelevant mAb control. IgG concentrations were determined by A\(280\) measurements.

**Bone marrow-derived mouse macrophage culture**

Bone marrow was isolated by flushing the femurs of female SCID mice (C.B-17/Icr-Prkdc\(^{scid}\)/Crl), purchased from Charles River, filtered and subsequently cultured for 7 d in DMEM (Lonza, BE12-079F) with 10% heat-inactivated CCS, 2 mM L-glutamine, 50 IU/ml penicillin, 50 \(\mu\)g/ml streptomycin (complete \(m_w\) medium) supplemented with 50 U/ml M-CSF (ProSpec, 315-02). \(M_w\) were detached with 0.5 mM EDTA (Versene, Gibco, 15040-033) and characterized by flow cytometry on a FACSCantoII (BD Biosciences) using F4/80-PE (Invitrogen, MF48004), CD80-PE (eBioscience, 12-0801), CD64-PE and CD32/16-FITC (BD Biosciences, 558455 and 553144, respectively) specific Ab.

**Monocyte-derived human macrophage culture**

PBMC were isolated from buffy coats obtained from regular blood bank donations (after informed consent, Sanquin Blood Bank, Utrecht, The Netherlands) using density separation with Lymphocyte Separation Medium (Lonza, US17-829E), followed by washing with PBS (B. Braun, 3623140). Monocytes were isolated via negative selection from the PBMC fraction using the Dynabeads Untouched Human Monocytes isolation kit (Invitrogen, 113.50D). Isolated monocytes were cultured for 7 d in complete \(m_w\) medium supplemented with 10 ng/ml GM-CSF (Invitrogen, PHC2015). \(M_w\) were detached with 0.1% trypsin-EDTA (Invitrogen, 15400-054) in PBS and characterized by flow cytometry (FACSCantoII) for staining with CD11b-PE (555388), CD32-FITC (552883), CD16-FITC (555406) from BD Biosciences and CD64-FITC (Biolegend, 305006).
Flow cytometry

CD38 cell surface expression was quantified using mouse-anti-human CD38 antibodies (BD Biosciences, 555458) and the Qfi kit (DAKO, K0078), according to the manufacturer’s guidelines. Samples were analyzed with flow cytometry (FACSCantOll).

Antibody-dependent phagocytosis

Mφ were seeded either at 2.5 × 10⁵ cells per well into 24-well plates or 1 × 10⁵ cells per well into 96-well plates and allowed to adhere. Target cells were labeled with calcein-AM (Invitrogen, C-3100) and added to the mφ at an effector:target (E:T) ratio of ~1:1 (mouse mφ) or ~2:1 (human mφ) in the presence of 6.7 nM mAb (equals 1 μg/ml IgG1 or 0.7 μg/ml F(ab')₂ fragments). After 4 h incubation at 37°C/5% CO₂ the supernatant containing non-phagocytosed target cells was collected. Mφ were detached with 0.1% trypsin-EDTA and subsequently added to the non-phagocytosed target cells. The pooled cells were kept at 4°C and stained with either anti-F4/80-PE (mouse mφ) or anti-CD11b-PE (human mφ) to identify mφ. Non-phagocytosed BL or MM target cells, either free or bound to macrophages, were detected using anti-CD19-APC (DAKO, C7224) or anti-CD138-APC (Beckman Coulter, PN A87787), respectively.

Antibody-dependent phagocytosis was assessed with flow cytometry (FACSCantOll), and quantified in 2 ways. First, as the percentage of mφ that had phagocytosed, determined using the percentage of F4/80⁺/calcein⁺ (mouse) or CD11b⁺/calcein⁺ (human) (double positive; DP) mφ. To exclude mφ only adhering to target cells (not engulfing), DP macrophages also positive for the BL or MM markers CD19 or CD138 were excluded from the DP population. For each sample, the total number of mφ in the sample (F4/80⁺ or CD11b⁺ cells) was used as 100% value. Second, phagocytosis was quantified by counting the number of remaining target cells (F4/80⁻ or CD11b⁻) with and without Ab treatment. To exclude elimination of target cells via additional killing mechanisms, like e.g. ADCC, which leads to loss of calcine through leakage of the plasma membrane, we included both calcine-negative and -positive cells when counting the number of remaining target cells. Elimination of target cells was calculated using the following formula:

\[
\text{% eliminated target cells} = 100 - \frac{\text{remaining target cells after Ab treatment}}{\text{remaining target cells without Ab treatment}} \times 100%
\]

The percentage DP mφ and the percentage of eliminated target cells showed substantial variation between experiments, most likely due to the use of different batches of cultured macrophages that originated from different donors. To allow comparisons between experiments with patient MM cells, Daudi cells were included in each experiment as an internal control. To correct for differences in levels of baseline phagocytosis between patient samples, we subtracted the percentages found with the irrelevant mAb control from the percentage observed in the presence of DARA. Results obtained using patient MM cells were normalized using the following formulas:

\[
\text{normalized DP mφ} = \frac{100 \times (\text{patient sample}(\% \text{ DP with DARA}) - \% \text{ DP with irrelevant mAb})}{\text{Daudi}(\% \text{ DP with DARA}) - \% \text{ DP with irrelevant mAb})}
\]

\[
\text{normalized eliminated target cells} = \frac{100 \times (\text{patient sample}(\% \text{ elimination with DARA}) - \% \text{ elimination with irrelevant mAb})}{\text{Daudi}(\% \text{ elimination with DARA}) - \% \text{ elimination with irrelevant mAb})}
\]

Live cell imaging

For live cell imaging, target cells and mouse mφ were incubated (1–10 × 10⁶ cells/ml) in HBSS (Gibco, 24020-091) or complete mφ medium, supplemented with 25 μg/ml of the fluorescent dyes DiB (Biotium, 60036) or 3,3’-dioctadecyloxacarbocyanine perchlorate (DiO, Molecular Probes Inc. D-275), respectively, for 30 minutes at 37°C, and subsequently washed 3 times with complete mφ medium. Mφ were seeded at 2 × 10⁵ cells/well into 8 wells ibiTreat µ-Slides (IBIDI, 80826) and allowed to adhere O/N. Real-time phagocytosis assays were performed with indicated E:T ratios at a fixed mAb concentration and imaged with an Olympus CellR real-time live-imaging station (type IX81, UPLFLN 40 × O/1.3 lens). Pictures were taken every 20 seconds with an Olympus ColorView II camera for 30 minutes.

Mouse tumor xenograft models

Experiments were performed with 8–12 weeks old female SCID-BEIGE mice (C.B-17/IcrHsd-Prkdc⁰scidLysbg), purchased from Harlan. Mice were housed in a barrier unit of the Central Laboratory Animal Facility (Utrecht, The Netherlands) and kept in individually ventilated cages with water and food provided ad libitum. Mice were checked at least twice a week for clinical signs of disease and discomfort. All experiments were approved by the Utrecht University animal ethics committee. Subcutaneous tumors were induced by inoculation of 20 × 10⁶ Daudi-luc cells in BD Matrigel Basement Membrane Matrix High Concentration (BD Biosciences, 354248) in the right flank of mice and tumor volumes were calculated from digital caliper measurements as 0.52 × length × width² (in mm³). Experimental leukemia was induced by injecting 2.5 × 10⁶ Daudi-luc cells into the tail vein. At weekly intervals, tumor growth was assessed using bioluminescence imaging on a Photon Imager (Biospace Lab). Before imaging, mice were anaesthetized via isoflurane and synthetic d-luciferin (Biothera, BT11–1000) was given i.p. at a dose of 125 mg/kg, M3 vision software (Biospace Lab) was used for image analysis. MAb were injected i.p. at day 0, after tumor cell inoculation, at indicated dosing levels. During the study, heparinized blood samples were taken for determination of IgG levels in plasma using a Behring Nephelometer II (Siemens Healthcare Diagnostics).

Statistical analysis

Data analysis was performed using GraphPad Prism 5.0 (Graphpad) and PASW Statistics 18.0 (SPSS Inc.) software.
Data were reported as mean ± SEM. Differences between groups were analyzed by one-way ANOVA with Bonferroni’s multiple comparison post-test (Prism) or Mantle-Cox log-rank test (PASW).

Disclosure of Potential Conflicts of Interest
MB Overdijk, S Verploegen, JJ Lammerts van Bueren, Esther Breij, WK Bleeker, PWHI Parren are Genmab employees and have Genmab warrant and/or stock. RWJ Groen, ACM Martens, T Mutis received research funding from Genmab.

References
1. Manches O, Lui G, Chaperot L, Gresin R, Molens JP, Jacob MC, Soto JJ, Leroux D, Bensa JC, Plumas J. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 2003; 101:949-54; PMID:12653572; http://dx.doi.org/10.1182/blood-2002-02-0460
2. Munn DH, McBride M, Cheung NK. Role of low-affinity Fc receptors in antibody-dependent tumor cell phagocytosis by human monocyte-derived macrophages. Cancer Res 1991; 51:1117-23; PMID:1825476
3. Mantovani A, Schioppa T, Porta C, Allavena P, Sica A. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev 2006; 25:315-32; PMID:16567732; http://dx.doi.org/10.1007/s10555-006-9001-7
4. Ribatti D, Moschetta M, Vacc A. Macrophages in multiple myeloma. Immunol Infect Lett 2014; 161:24-1; PMID:24376642
5. Zheng Y, Cai Z, Wang S, Zhang X, Qian J, Hong S, Li H, Wang M, Yang J, Yi Q. Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. Blood 2009; 114:3625-8; PMID:19710503; http://dx.doi.org/10.1182/blood-2009-05-220285
6. Uchida J, Hamaguchi Y, Oliver JA, Ravetch JV, Poe JC, Haas KM, Tedder TF. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 2004; 199:1659-69; PMID:15210744; http://dx.doi.org/10.1084/jem.20040118
7. Møller-Colin V, Xia Y, Poe JC, Horikawa M, Magro CM, Hamaguchi Y, Haas KM, Tedder TF. Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRIIa, FcgammaRIIIa, and FcgammaRIIIb. Blood 2008; 112:1207-15; PMID:18493935; http://dx.doi.org/10.1182/blood-2008-01-135160
8. McEarchern JA, Olfangiu E, Francisco L, McDonagh CF, Gordon KA, Stone I, Klaussman K, Turcott E, van Rooijen N, Carter P, Grewal IS, Wahl AF, Law CL. Inhibiting C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. J Immunol 2000; 164:4178-84; PMID:10754313; http://dx.doi.org/10.4049/jimmunol.164.8.4178
9. Overdijk MB, Verploegen S, Ortiz Bujisse A, Vink T, Leusink JH, Totpal K, van den Winkel JG, Parren PW. Crosstalk between human IgF isotypes and murine effector cells. J Immunol 2012; 189:3430-4; PMID:22956577; http://dx.doi.org/10.4049/jimmunol.1200356
10. Overdijk MB, Verploegen S, van den Brakel JH, Lammers van Bueren J, Vink T, van de Winkel JG, Parren PW, Bleeker WK. Epidermal growth factor receptor (EGFR) antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibition. J Immunol 2011; 187:3383-90; PMID:21382160; http://dx.doi.org/10.4049/jimmunol.1003926
11. Lei G, Mehta K, Malavasi F. Human CD38 and related molecules. Basel: Karger, SAG; 2000.
12. Schneider-Merck T, Lammerts van Bueren JJ, Berger S, Rosen K, van Berkel PH, Deter S, Beyer T, Lohse S, Bleeker WK, Peipp M, et al. Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in

Supplemental Material
Supplemental data for this article can be accessed on the publisher’s website.

Acknowledgment
The authors express their thanks to Berris van Kessel for technical assistance.
contrast to IgG1, only by cells of myeloid lineage. J Immunol 2010; 184:512-20; PMID:19949082; http://dx.doi.org/10.4049/jimmunol.0900847.

33. Montalvao F, Garcia Z, Colli S, Breart B, Deguine J, Van Rooijen N, Bousso P. The mechanism of anti-CD20-mediated B cell depletion revealed by intravital imaging. J Clin Invest 2013; 123:5098-103; PMID:23109694; http://dx.doi.org/10.1172/JCI70972.

34. van der Veer MS, de Weers M, van Kessel B, Bakker JM, Wittebol S, Parent PW, Lokhorst HM, Mutis T. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica 2011; 96:284-90; PMID:213109694; http://dx.doi.org/10.3324/haematol.2010.030759.

35. Gimsing P, Plesner T, Nahi H, Lokhorst H, Valentijn M-L, Lisby S, Richardson PG. A phase IIF, dose-escalation study of daratumumab, a CD38 mab in patients with multiple myeloma - preliminary safety data. ASH Annu Meeting Abstr 2013; 158:1873.

36. Plesner T, Lokhorst H, Gimsing P, Nahi H, Lisby S, Richardson PG. Daratumumab, a CD38 monoclonal antibody in patients with multiple myeloma - data from a dose-escalation phase IIF study. ASH Annu Meeting Abstr 2013; 120:73.

37. van de Donk NW, Kamps S, Mutis T, Lokhorst HM. Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma. Leukemia 2012; 26:199-213; PMID:21852787; http://dx.doi.org/10.1038/leu.2011.214.

38. Ocio EM, Richardson PG, Rajkumar SV, Palumbo A, Mateos MV, Orlowski R, Kumar S, Uzmani S, Roodman D, Niesvizky R, et al. New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia 2014; 28:525-42; PMID:24253022; http://dx.doi.org/10.4049/jimmunol.1400154.

39. Quach H, Ritchie D, Stewart AK, Neeson P, Harrison S, Smyth MJ, Prince HM. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia 2010; 24:22-32; PMID:19907457; http://dx.doi.org/10.1038/leu.2009.236.

40. Grugan KD, McCabe FL, Kinder M, Greenplate AR, Harman BC, Ekert JE, van Rooijen N, Anderson GM, Nemeth JA, Stohl WR, et al. Tumor-associated macrophages promote invasion while retaining Fc-dependent anti-tumor function. J Immunol 2012; 189:5457-66; PMID:23105143; http://dx.doi.org/10.4049/jimmunol.1201889.

41. Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, Jan M, Cha AC, Chan CK, Tan BT, et al. Anti-CD38 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 2010; 142:699-713; PMID:20813259; http://dx.doi.org/10.1016/j.cell.2010.07.044.

42. Winkelkopf K, Ring AM, Ho CC, Volkmer JF, Leveque LM, Volkmer AK, Otkan E, Fernhoff NB, van de Rijn M, Weissman IL, et al. Engineered SIRPalpha variants as immunotherapeutic adjuvants to anticancer antibodies. Science 2013; 341:88-91; PMID:23722425; http://dx.doi.org/10.1126/science.1238856.

43. Zhao XW, van Beek EM, Schornagel K, Van der Maaden H, Van Houtr M, Orten MA, Finetti P, Van Egmond M, Marozaki T, Kraal G, et al. CD47-signal regulatory protein-alpha (SIRPa/alpha) interactions form a barrier for antibody-mediated tumor cell destruction. Proc Natl Acad Sci U S A 2011; 108:18342-7; PMID:22042861; http://dx.doi.org/10.1073/pnas.1006550108.

44. Kim D, Wang J, Willingham SB, Martin R, Wernig G, Weismann IL. Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells. Leukemia 2012; 26:2538-45; PMID:22648449; http://dx.doi.org/10.1038/leu.2012.141.

45. Kuipers J, Vaandragter JW, Weghuis DO, Pearson PL, Schers J, Lokhorst HM, Clevers H, Bart BJ. Fluorescence in situ hybridization analysis shows the frequent occurrence of 14q32.3 rearrangements with involvement of immunoglobulin switch regions in myeloma cell lines. Cancer Genet Cytogenet 2010; 199:99-107; PMID:21087940; http://dx.doi.org/10.1016/j.ssc.2010.04.015.

46. Rozemuller H, van der Spek E, Rogers-Boer LH, Zwart MC, Verweij V, Emmelot M, Groen RW, Spaapen R, Bloem AC, Lokhorst HM, et al. A bioluminescence imaging based in vivo model for preclinical testing of novel cellular immunotherapy strategies to improve the graft-versus-myeloma effect. Haematologica 2008; 93:1049-57; PMID:18492693; http://dx.doi.org/10.3324/haematol.12349.

47. Burton DR, Pyati J, Koduri R, Sharp SJ, Thornton GB, Parren PW, Sawyer LS, Hendry RM, Dunlop N, Nara PL, et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994; 266:1024-7; PMID:7973652; http://dx.doi.org/10.1126/science.7973652.